StockSignal
  • Screen for fundamentally interesting stocks
Sign in
MeHow Innovative Ltd. logo

MeHow Innovative Ltd.

301363 · XSHE · Medical Devices · China

Book Value Growing 3yFcf Positive 3yNet Profit MarginProfitable 3y
Market Capitalization15.34B CNY
Trailing P/E50.43 CNY
52-Week Change24.63 CNY
Forward Annual Dividend Yield0.59%
Beta0.7540 CNY

MeHow Innovative Ltd. is a leading company specializing in the research, development, and manufacture of advanced medical devices and precision healthcare components. The company plays a pivotal role in the medical technology sector, primarily focusing on creating innovative solutions that enhance patient care and healthcare efficiency. MeHow Innovative Ltd. is well-regarded for its cutting-edge product lineup, which includes precision-engineered components for medical diagnostics and therapeutic equipment, helping to set benchmarks in product quality and reliability. Its technological capabilities serve critical functions in various healthcare applications, impacting hospitals, clinics, and medical professionals worldwide. Headquartered in China, MeHow Innovative Ltd. underscores the growing importance of Asian markets in the global medical technology landscape, contributing to advancements in healthcare accessibility and effectiveness. The company's market role is crucial as it continues to drive innovation while adhering to stringent regulatory standards and addressing the evolving needs of the healthcare industry.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in MeHow Innovative Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
15.34BCNY
NormalMar 18, 2026
Trailing P/E
50.43CNY
AboveNormalMar 18, 2026
Revenue (TTM)
1.63BCNY
NormalMar 18, 2026
Profit Margin
19.25%
NormalMar 18, 2026
Beta
0.7540CNY
NormalMar 18, 2026
52-Week Change
24.63CNY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
0.59%
NormalMar 18, 2026
Forward Yield
0.59%
Annual Rate
CNY 0.16
Paid semi-annual
Payout Ratio
12.7%
Sustainable
Loading dividend history...

Track Record

Frequency
Semi-Annual
Payback Period
169.4 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Dec 8, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation8
Market Capitalization
15.34BCNY
NormalMar 18, 2026
Enterprise Value
14.67BCNY
NormalMar 18, 2026
Trailing P/E
50.43CNY
AboveNormalMar 18, 2026
Forward P/E
35.31CNY
AboveNormalMar 18, 2026
Price to Sales (TTM)
9.84CNY
NormalMar 18, 2026
Price to Book (MRQ)
4.32CNY
NormalMar 18, 2026
Enterprise to Revenue
8.99CNY
NormalMar 18, 2026
Enterprise to EBITDA
37.67CNY
AboveNormalMar 18, 2026
Profitability & Growth53
Gross Margin
36.33%
NormalMar 18, 2026
Profit Margin
19.25%
NormalMar 18, 2026
Operating Margin
25.38%
NormalMar 18, 2026
Return on Assets (TTM)
0.0460CNY
NormalMar 18, 2026
Return on Equity (TTM)
0.0886CNY
NormalMar 18, 2026
Revenue (TTM)
1.63BCNY
NormalMar 18, 2026
Revenue per Share (TTM)
2.92CNY
NormalMar 18, 2026
Quarterly Revenue Growth
0.0260CNY
NormalMar 18, 2026
Gross Profit (TTM)
643.61MCNY
NormalMar 18, 2026
EBITDA
369.34MCNY
ExtremeMar 18, 2026
Net Income (TTM)
314.13MCNY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
0.0590CNY
NormalMar 18, 2026
Operating Cash Flow (TTM)
368.44MCNY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
-323.32MCNY
NormalMar 18, 2026
Forward Annual Dividend Rate
0.1600CNY
NormalMar 18, 2026
Forward Annual Dividend Yield
0.59%
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.1514CNY
NormalMar 18, 2026
Trailing Annual Dividend Yield
0.56%
NormalMar 18, 2026
Payout Ratio
0.1269CNY
NormalMar 18, 2026
Revenue
1.59B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
923.40M
NormalFY2024 · Dec 31, 2024
Gross Profit
670.81M
NormalFY2024 · Dec 31, 2024
Operating Income
372.22M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
410.25M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
46.48M
NormalFY2024 · Dec 31, 2024
Net Income
363.78M
NormalFY2024 · Dec 31, 2024
EBIT
410.25M
NormalFY2024 · Dec 31, 2024
ebitda-income
529.53M
NormalFY2024 · Dec 31, 2024
Research & Development
140.58M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
44.15M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
15.83M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
42.68M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
0.00
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.6429
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.6429
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
565.87MShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
565.87MShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
363.78M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
250.17M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
85.13M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
818.11M
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
363.78M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
-12.94M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-135.06M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
34.39M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-353.84M
NormalFY2024 · Dec 31, 2024
Sale of Investments
10.05M
NormalFY2024 · Dec 31, 2024
Other Investing Activity
-384.28M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-728.06M
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-64.81M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-57.55M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-122.35M
NormalFY2024 · Dec 31, 2024
Financial Strength30
Shares Outstanding
568.87MShares
NormalMar 18, 2026
Float Shares
143.57MCNY
NormalMar 18, 2026
% Held by Insiders
0.7481CNY
NormalMar 18, 2026
% Held by Institutions
0.0843CNY
NormalMar 18, 2026
Total Cash (MRQ)
1.62BCNY
NormalMar 18, 2026
Total Cash per Share (MRQ)
2.85CNY
NormalMar 18, 2026
Total Debt (MRQ)
63.42MCNY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
1.71CNY
NormalMar 18, 2026
Current Ratio (MRQ)
6.05CNY
AboveNormalMar 18, 2026
Book Value per Share (MRQ)
6.53CNY
NormalMar 18, 2026
Total Assets
3.92B
NormalFY2024 · Dec 31, 2024
Total Current Assets
2.46B
NormalFY2024 · Dec 31, 2024
Total Liabilities
441.96M
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
1.46B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
69.60M
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
372.36M
NormalFY2024 · Dec 31, 2024
Cash
1.03B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
221.51M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
1.25B
NormalFY2024 · Dec 31, 2024
Other Short-term Investments
491.73M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
344.63M
NormalFY2024 · Dec 31, 2024
Inventory
329.50M
NormalFY2024 · Dec 31, 2024
Accounts Payable
216.08M
NormalFY2024 · Dec 31, 2024
Short-term Debt
6.12M
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
1.65M
NormalFY2024 · Dec 31, 2024
Long-term Debt
9.17M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
406.66M
NormalFY2024 · Dec 31, 2024
Retained Earnings
1.39B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
3.48B
NormalFY2024 · Dec 31, 2024
Treasury Stock
50.10M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
16.09CNY
NormalMar 18, 2026
52-Week High
43.30CNY
NormalMar 18, 2026
52-Week Change
24.63CNY
ExtremeMar 18, 2026
Beta
0.7540CNY
NormalMar 18, 2026
50-Day MA
32.70CNY
NormalMar 18, 2026
200-Day MA
24.39CNY
NormalMar 18, 2026
Avg 10-Day Volume
13.85MCNY
NormalMar 18, 2026
Avg 30-Day Volume
13.23MCNY
NormalMar 18, 2026
Diluted EPS (TTM)
0.5600CNY
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.